Table 2.
Randomized controlled trials investigating the effect of magnesium supplementation on CRP in humans.
| Study | Country | Intervention group | Control group | Duration | Outcome Measure | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| n/N | Male, % | Age, year | Treatment | n/N | Male, % | Age, year | Treatment | ||||
| Almoznino-Sarafian, et al., 2007(25) | Israel | 17/17 | 52.9 | 71.0±7.8 | Oral magnesium citrate: 300 mg/day | 18/18 | 55.6 | 72.38 | Untreated Controls | 5 weeks | ln(CRP) ± SD; Pearson’s correlation coefficient |
| Chacko, et al., 2010(27) | USA | 13/14 | 71 | 44.4 ±13.0 | Oral magnesium citrate: 500 mg/day | 13/14 | 71 | 44.4 ± 13.0 | Placebo | 4 weeks | Geometric mean (95%CI) |
| Nielsen, et al., 2010(26) | USA | 46/50 | 22 | 51–85 | Oral magnesium citrate: 320 mg/day | 49/50 | 22 | 51–85 | Placebo (Sodium Citrate) | 8 weeks | Change in mean CRP (increase/decrease) |
| Rodriguez-Hernandez, et al., 2010(33) | Mexico | 15/20 | 0 | 30–65 | Oral Solution containing 50ml of 5% Magnesium Chloride (equivalent to 450 mg/day elemental magnesium) | 15/18 | 0 | 30–65 | Control | 4 months | Mean CRP ± SD; OR for reduction in CRP |
| Mosleh, et al., 2012(32) | Iran | 35/37 | 0 | 46.3±4.2 | Oral Magnesium Oxide: 250mg/day | 34/37 | 0 | 46.3±4.2 | Placebo | 8 weeks | Median (IQR) for CRP |
Abbreviations: n in n/N is the number of participants who completed the study in each arm; and N is the number of participants who started the study in each arm; CRP: C-reactive protein; IQR: inter-quartile range; SD: standard deviation.